Vittoria's lead program, Viper 101, is a promising gene-edited cell therapy specifically designed for T-cell lymphoma. With the support of MaxCyte's Flow Electroporation® technology and ExPERT™ platform, Vittoria plans to file an investigational new drug application (IND) for this groundbreaking therapy. This collaboration will not only enhance the manufacturing process of Vittoria's CAR-T cells but also improve their efficacy and safety.
MaxCyte's ExPERT™ platform has proven to be a game-changer in the field of cell-based medicines. Its ability to deliver high transfection efficiency and scalability makes it an ideal choice for next-generation therapies. The partnership with Vittoria marks MaxCyte's 22nd strategic platform license, further establishing their position as a leader in cell engineering.